News & Updates

Combination treatment with esketamine plus either a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI) is beneficial in treatment-resistant depression (TRD), with notable variations in outcomes depending on the choice of antidepressant class, as shown in a large retrospective study.

A considerable number of individuals who have received a diagnosis of major depressive disorder show little to no improvement despite having tried multiple antidepressant medications, according to new research.

Cognitive impairment or dementia is present in 18.7 percent of community-dwelling older adults in Hong Kong – a prevalence higher than rates reported in previous research – according to a cross-sectional study.